RU2016135417A - Новый анализ для детектирования периостина человека - Google Patents
Новый анализ для детектирования периостина человека Download PDFInfo
- Publication number
- RU2016135417A RU2016135417A RU2016135417A RU2016135417A RU2016135417A RU 2016135417 A RU2016135417 A RU 2016135417A RU 2016135417 A RU2016135417 A RU 2016135417A RU 2016135417 A RU2016135417 A RU 2016135417A RU 2016135417 A RU2016135417 A RU 2016135417A
- Authority
- RU
- Russia
- Prior art keywords
- periostin
- patient
- level
- sample
- antibody
- Prior art date
Links
- 238000001514 detection method Methods 0.000 title claims 23
- 238000004458 analytical method Methods 0.000 title claims 17
- 101710199268 Periostin Proteins 0.000 claims 176
- 102100037765 Periostin Human genes 0.000 claims 176
- 239000012634 fragment Substances 0.000 claims 81
- 238000000034 method Methods 0.000 claims 80
- 239000000523 sample Substances 0.000 claims 74
- 239000000427 antigen Substances 0.000 claims 69
- 108091007433 antigens Proteins 0.000 claims 69
- 102000036639 antigens Human genes 0.000 claims 69
- 210000004408 hybridoma Anatomy 0.000 claims 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 37
- 239000005557 antagonist Substances 0.000 claims 29
- 102000001708 Protein Isoforms Human genes 0.000 claims 25
- 108010029485 Protein Isoforms Proteins 0.000 claims 25
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 20
- 238000010324 immunological assay Methods 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 19
- 208000035475 disorder Diseases 0.000 claims 18
- 230000001900 immune effect Effects 0.000 claims 18
- 230000001404 mediated effect Effects 0.000 claims 14
- 101001095308 Homo sapiens Periostin Proteins 0.000 claims 10
- 102000048431 human POSTN Human genes 0.000 claims 10
- 210000004072 lung Anatomy 0.000 claims 10
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 9
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 8
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 7
- 208000037976 chronic inflammation Diseases 0.000 claims 7
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 208000006673 asthma Diseases 0.000 claims 6
- 239000013610 patient sample Substances 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 208000017520 skin disease Diseases 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 238000011269 treatment regimen Methods 0.000 claims 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims 5
- 201000008937 atopic dermatitis Diseases 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 4
- 229960002685 biotin Drugs 0.000 claims 4
- 235000020958 biotin Nutrition 0.000 claims 4
- 239000011616 biotin Substances 0.000 claims 4
- 239000013522 chelant Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229910052707 ruthenium Inorganic materials 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 3
- 238000003748 differential diagnosis Methods 0.000 claims 3
- 210000003979 eosinophil Anatomy 0.000 claims 3
- 229940126585 therapeutic drug Drugs 0.000 claims 3
- 229950000835 tralokinumab Drugs 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 1
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461936967P | 2014-02-07 | 2014-02-07 | |
| US61/936,967 | 2014-02-07 | ||
| PCT/US2015/014671 WO2015120185A1 (en) | 2014-02-07 | 2015-02-05 | Novel assay to detect human periostin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016135417A true RU2016135417A (ru) | 2018-03-12 |
| RU2016135417A3 RU2016135417A3 (enExample) | 2018-10-31 |
Family
ID=52574429
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016135417A RU2016135417A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
| RU2016135418A RU2016135418A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016135418A RU2016135418A (ru) | 2014-02-07 | 2015-02-05 | Новый анализ для детектирования периостина человека |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9862762B2 (enExample) |
| EP (2) | EP3102601B1 (enExample) |
| JP (3) | JP6549132B2 (enExample) |
| KR (2) | KR20160125409A (enExample) |
| CN (2) | CN106170497A (enExample) |
| AU (2) | AU2015214103A1 (enExample) |
| BR (2) | BR112016017901A2 (enExample) |
| CA (2) | CA2936285A1 (enExample) |
| HK (2) | HK1232290A1 (enExample) |
| MX (2) | MX2016009450A (enExample) |
| RU (2) | RU2016135417A (enExample) |
| SG (2) | SG11201606322XA (enExample) |
| TW (1) | TW201542589A (enExample) |
| WO (2) | WO2015120185A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018538249A (ja) | 2015-11-04 | 2018-12-27 | アストラゼネカ アクチボラグ | 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン |
| WO2018030456A1 (ja) * | 2016-08-10 | 2018-02-15 | 株式会社シノテスト | 試料に含まれるペリオスチンの測定試薬、ペリオスチン測定用前処理剤、ペリオスチン測定方法及びペリオスチン測定の感度の改善方法 |
| JPWO2018194134A1 (ja) * | 2017-04-20 | 2020-02-27 | 株式会社シノテスト | 抗ペリオスチン抗体固定化担体、ペリオスチン測定試薬、及び抗ペリオスチン抗体固定化担体における抗体の安定化方法 |
| WO2019183131A1 (en) | 2018-03-19 | 2019-09-26 | Bioventures, Llc | Periostin antibodies and methods of using the same |
| CN109879963A (zh) * | 2019-03-15 | 2019-06-14 | 辽宁何氏医学院 | 一种抑制组织器官纤维化和新生血管形成的单克隆抗体及其制备方法和应用 |
| CA3138237A1 (en) | 2019-04-26 | 2020-10-29 | Cornell University | Klebsiella vaccine and methods of use |
| US20250035618A1 (en) * | 2021-12-28 | 2025-01-30 | Sekisui Medical Co., Ltd. | Detection method and detection reagent |
| CN115078734A (zh) * | 2022-06-15 | 2022-09-20 | 苏州方达新药开发有限公司 | 一种细胞因子融合蛋白的检测分析方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| CN101189033B (zh) | 2005-05-30 | 2012-03-28 | 株式会社器官再生工学 | 牙齿的制造方法、牙齿的集合体及组织的制造方法 |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| AU2006334029B2 (en) * | 2005-12-28 | 2013-01-31 | Osaka University | An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved |
| US8017119B2 (en) | 2005-12-28 | 2011-09-13 | Daiichi Sankyo Company, Ltd. | Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved |
| KR101560843B1 (ko) | 2007-06-27 | 2015-10-15 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제 |
| RU2607569C2 (ru) | 2008-03-31 | 2017-01-10 | Дженентек, Инк. | Композиции и способы для лечения и диагностики астмы |
| WO2009126304A1 (en) | 2008-04-11 | 2009-10-15 | Biogen Idec Ma Inc. | Therapeutic combinations of anti-igf-1r antibodies and other compounds |
| FR2946349B1 (fr) | 2009-06-03 | 2013-10-04 | Synarc Sas | Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine |
| KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| EP2710143B1 (en) | 2011-05-18 | 2016-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for determining whether a subject is at risk of having or developing a chronic kidney disease |
| US8961965B2 (en) | 2011-05-18 | 2015-02-24 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| US9347954B2 (en) | 2011-09-06 | 2016-05-24 | Shino-Test Corporation | Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same |
| JP5797148B2 (ja) | 2011-09-12 | 2015-10-21 | 富士フイルム株式会社 | コレステリック液晶性混合物、フィルム、選択反射板、積層体および合わせガラス |
| EA201490576A1 (ru) * | 2011-09-15 | 2014-09-30 | Нэшенел Юнивёрсити Корпорейшен Нагоя Юнивёрсити | Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии |
| CA2865154A1 (en) | 2012-02-24 | 2013-08-29 | Children's Hospital Medical Center | Esophageal microrna expression profiles in eosinophilic esophagitis |
| PL2875049T3 (pl) | 2012-07-18 | 2019-07-31 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd) |
| KR20160113700A (ko) * | 2014-01-27 | 2016-09-30 | 메디뮨 엘엘씨 | 천식 폐에서의 il-13 활성화의 말초 바이오마커로서의 디펩티딜 펩티다제-4(dpp4/cd26) |
-
2015
- 2015-02-05 AU AU2015214103A patent/AU2015214103A1/en not_active Abandoned
- 2015-02-05 HK HK17105816.2A patent/HK1232290A1/zh unknown
- 2015-02-05 BR BR112016017901A patent/BR112016017901A2/pt not_active Application Discontinuation
- 2015-02-05 JP JP2016544101A patent/JP6549132B2/ja not_active Expired - Fee Related
- 2015-02-05 HK HK17105868.9A patent/HK1232238A1/zh unknown
- 2015-02-05 MX MX2016009450A patent/MX2016009450A/es unknown
- 2015-02-05 BR BR112016017926A patent/BR112016017926A2/pt not_active IP Right Cessation
- 2015-02-05 MX MX2016009490A patent/MX2016009490A/es unknown
- 2015-02-05 WO PCT/US2015/014671 patent/WO2015120185A1/en not_active Ceased
- 2015-02-05 SG SG11201606322XA patent/SG11201606322XA/en unknown
- 2015-02-05 SG SG10201806729VA patent/SG10201806729VA/en unknown
- 2015-02-05 EP EP15706091.4A patent/EP3102601B1/en active Active
- 2015-02-05 KR KR1020167024163A patent/KR20160125409A/ko not_active Withdrawn
- 2015-02-05 KR KR1020167024160A patent/KR20160122756A/ko not_active Withdrawn
- 2015-02-05 CN CN201580007504.9A patent/CN106170497A/zh active Pending
- 2015-02-05 EP EP15706093.0A patent/EP3102951A1/en not_active Withdrawn
- 2015-02-05 CA CA2936285A patent/CA2936285A1/en not_active Abandoned
- 2015-02-05 US US15/104,502 patent/US9862762B2/en active Active
- 2015-02-05 RU RU2016135417A patent/RU2016135417A/ru not_active Application Discontinuation
- 2015-02-05 CA CA2936258A patent/CA2936258A1/en not_active Abandoned
- 2015-02-05 CN CN201580007503.4A patent/CN106164675B/zh not_active Expired - Fee Related
- 2015-02-05 WO PCT/US2015/014652 patent/WO2015120171A1/en not_active Ceased
- 2015-02-05 RU RU2016135418A patent/RU2016135418A/ru not_active Application Discontinuation
- 2015-02-05 US US15/106,223 patent/US10775388B2/en active Active
- 2015-02-05 AU AU2015214089A patent/AU2015214089A1/en not_active Abandoned
- 2015-02-05 JP JP2016545358A patent/JP2017506064A/ja active Pending
- 2015-02-06 TW TW104104194A patent/TW201542589A/zh unknown
-
2017
- 2017-11-22 US US15/821,716 patent/US20180179272A1/en not_active Abandoned
-
2019
- 2019-07-30 JP JP2019139534A patent/JP2020000236A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016135417A (ru) | Новый анализ для детектирования периостина человека | |
| US12105098B2 (en) | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) | |
| AU2018378084A1 (en) | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 | |
| JP2013527444A (ja) | 抗体を検出するための方法 | |
| JP2018535394A5 (enExample) | ||
| JP2012516431A (ja) | 糖尿病性ネフロパシーに関連する尿および血清のバイオマーカー | |
| CN111487419B (zh) | Kl-6在儿童新冠肺炎中的应用 | |
| CN107345970A (zh) | 一种可用于首发精神分裂症诊断的外周血生物标志物 | |
| CN116660522A (zh) | 定量il-33的方法和组合物 | |
| US11009506B2 (en) | Kit for rapid diagnosis of asthma or allergy disease | |
| JP7130313B2 (ja) | 新規抗ウロモジュリン抗体、その抗体を使用した血中ウロモジュリン濃度の測定方法及び測定キット、並びに、そのキットを用いた腎機能の評価方法 | |
| US9442120B2 (en) | Biomarkers associated with nephropathy | |
| CN110320368A (zh) | 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用 | |
| WO2022181333A1 (ja) | 軽度認知障害検査 | |
| WO2015174544A1 (ja) | 精神疾患判定マーカー | |
| EP2924437B1 (en) | Method for detecting neurological disease accompanied by inflammation and/or demyelination | |
| US20230295684A1 (en) | Methods of diagnosing brain injury | |
| US20250277789A1 (en) | Method of improving prediction accuracy and reducing false negative rate of severe dengue prediction in subject | |
| EP2791673A1 (en) | Lamin a/c and prelamins as indicators of frailty and vulnerability or resiliency to adverse health outcomes | |
| WO2024038185A1 (en) | Method of selecting patients for treatment with an il-33 axis antagonist | |
| US20220268774A1 (en) | Method of elevating prediction accuracy of grouping subjects with severe dengue infection | |
| WO2018132639A1 (en) | Methods and kits for the diagnosis and/or prognosis of ocular cicatricial pemphigoid | |
| WO2025115009A1 (en) | Peptides for urinary diagnostics and antibodies for their detection | |
| TW202532443A (zh) | 抗－硫酸酯酶相關抗原的專一性抗體、包含抗－硫酸酯酶相關抗原的專一性抗體的檢驗套組及抗－硫酸酯酶相關抗原的專一性抗體用於檢測骨關節炎的用途 | |
| US20060211047A1 (en) | Test kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190218 |